Morphea: Evidence-based recommendations for treatment

Indian Journal of Dermatology, Venereology and Leprology

Volumn 78, Issue 2, 2012, Pages 135-140

  Fett, Nicole ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Evidenced based therapy; localized scleroderma; morphea; morphea treatment recommendations

Indexed keywords

BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CALCIPOTRIOL; CALCITRIOL; GAMMA INTERFERON; IMIQUIMOD; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

DRUG EFFICACY; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; HUMAN; MORPHEA; PHOTODYNAMIC THERAPY; PUVA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SYSTEMIC THERAPY; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION;

ALGORITHMS; DERMATOLOGY; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCLERODERMA, LOCALIZED;

EID: 84859307733     PISSN: 03786323     EISSN: 09733922     Source Type: Journal    
DOI: 10.4103/0378-6323.93628     Document Type: Review

References (46)

1. Batchelor R, Lamb S, Goulden V, Stables G, Goodfield M, Merchant W. Photodynamic therapy for the treatment of morphoea. Clin Exp Dermatol 2008;33:661-3.
2. Hunzelmann N, Anders S, Fierlbeck G, Hein R, Herrmann K, Albrecht M, et al. Double-blind, placebo-controlled study of intralesional interferon gamma for the treatment of localized scleroderma. J Am Acad Dermatol 1997;36:433-5.
3. Hulshof MM, Bouwes Bavinck JN, Bergman W, Masclee AA, Heickendorff L, Breedveld FC, et al. Double-blind, placebocontrolled study of oral calcitriol for the treatment of localized and systemic scleroderma. J Am Acad Dermatol 2000;43:1017-23.
4. Kroft EB, Groeneveld TJ, Seyger MM, de Jong EM. Efficacy of topical tacrolimus 0.1% in active plaque morphea: Randomized, double-blind, emollient-controlled pilot study. Am J Clin Dermatol 2009;10:181-7.
5. Kreuter A, Hyun J, Stucker M, Sommer A, Altmeyer P, Gambichler T. A randomized controlled study of low-Dose UVA1, medium-Dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol 2006;54:440-7.
6. Zulian F, Martini G, Vallongo C, Vittadello F, Falcini F, Patrizi A, et al. Methotrexate in juvenile localized scleroderma: A randomised, double-blind, placebo-controlled trial. Arthritis Rheum 2011;63:1998-2006.
7. Dytoc M, Ting PT, Man J, Sawyer D, Fiorillo L. First case series on the use of imiquimod for morphoea. Br J Dermatol 2005;153:815-20.
8. Dytoc MT, Kossintseva I, Ting PT. First case series on the use of calcipotriol-betamethasone dipropionate for morphoea. Br J Dermatol 2007;157:615-8.
9. Cunningham BB, Landells ID, Langman C, Sailer DE, Paller AS. Topical calcipotriene for morphea/linear scleroderma. J Am Acad Dermatol 1998;39:211-5.
10. Kerscher M, Dirschka T, Volkenandt M. Treatment of localised scleroderma by UVA1 phototherapy. Lancet 1995;346:1166.
11. Gruss C, Reed JA, Altmeyer P, McNutt NS, Kerscher M. Induction of interstitial collagenase (MMP-1) by UVA-1 phototherapy in morphea fibroblasts. Lancet 1997;350:1295-6.
12. Stege H, Berneburg M, Humke S, Klammer M, Grewe M, Grether-Beck S, et al. High-Dose UVA1 radiation therapy for localized scleroderma. J Am Acad Dermatol 1997;36:938-44.
13. Kerscher M, Volkenandt M, Gruss C, Reuther T, von Kobyletzki G, Freitag M, et al. Low-Dose UVA phototherapy for treatment of localized scleroderma. J Am Acad Dermatol 1998;38:21-6.
14. Gruss CJ, Von Kobyletzki G, Behrens-Williams SC, Lininger J, Reuther T, Kerscher M, et al. Effects of low dose ultraviolet A-1 phototherapy on morphea. Photodermatol Photoimmunol Photomed 2001;17:149-55.
15. Sator PG, Radakovic S, Schulmeister K, Honigsmann H, Tanew A. Medium-Dose is more effective than low-Dose ultraviolet A1 phototherapy for localized scleroderma as shown by 20-MHz ultrasound assessment. J Am Acad Dermatol 2009;60:786-91.
16. De Rie MA, Enomoto DN, de Vries HJ, Bos JD. Evaluation of medium-Dose UVA1 phototherapy in localized scleroderma with the cutometer and fast Fourier transform method. Dermatology 2003;207:298-301.
17. Kreuter A, Gambichler T, Avermaete A, Jansen T, Hoffmann M, Hoffmann K, et al. Combined treatment with calcipotriol ointment and low-Dose ultraviolet A1 phototherapy in childhood morphea. Pediatr Dermatol 2001;18:241-5.
18. Andres C, Kollmar A, Mempel M, Hein R, Ring J, Eberlein B. Successful ultraviolet A1 phototherapy in the treatment of localized scleroderma: A retrospective and prospective study. Br J Dermatol 2010;162:445-7.
19. Usmani N, Murphy A, Veale D, Goulden V, Goodfield M. Photochemotherapy for localized morphoea: Effect on clinical and molecular markers. Clin Exp Dermatol 2008;33:698-704.
20. Kerscher M, Meurer M, Sander C, Volkenandt M, Lehmann P, Plewig G, et al. PUVA bath photochemotherapy for localized scleroderma. Evaluation of 17 consecutive patients. Arch Dermatol 1996;132:1280-2.
21. El-Mofty M, Zaher H, Bosseila M, Yousef R, Saad B. Low-Dose broad-band UVA in morphea using a new method for evaluation. Photodermatol Photoimmunol Photomed 2000;16:43-9.
22. El-Mofty M, Mostafa W, El-Darouty M, Bosseila M, Nada H, Yousef R, et al. Different low doses of broad-band UVA in the treatment of morphea and systemic sclerosis. Photodermatol Photoimmunol Photomed 2004;20:148-56.
23. Kreuter A, Gambichler T, Breuckmann F, Rotterdam S, Freitag M, Stuecker M, et al. Pulsed high-Dose corticosteroids combined with low-Dose methotrexate in severe localized scleroderma. Arch Dermatol 2005;141:847-52.
24. Seyger MM, van den Hoogen FH, de Boo T, de Jong EM. Lowdose methotrexate in the treatment of widespread morphea. J Am Acad Dermatol 1998;39:220-5.
25. Uziel Y, Feldman BM, Krafchik BR, Yeung RS, Laxer RM. Methotrexate and corticosteroid therapy for pediatric localized scleroderma. J Pediatr 2000;136:91-5.
26. Martini G, Ramanan AV, Falcini F, Girschick H, Goldsmith DP, Zulian F. Successful treatment of severe or methotrexateresistant juvenile localized scleroderma with mycophenolate mofetil. Rheumatology 2009;48:1410-3.
27. United States. Prevention Services Task Force. Guide to clinical preventive services: Report of the U.S. Preventive Services Task Force; Preface by Robert S. Lawrence. Washington: Task Force; 1989.
28. Fett N, Werth VP. Update on morphea: Part II. Outcome measures and treatment. J Am Acad Dermatol 2011;64:231-42.
29. Kroft EB, Creemers MC, van den Hoogen FH, Boezeman JB, de Jong EM. Effectiveness, side-effects and period of remission after treatment with methotrexate in localized scleroderma and related sclerotic skin diseases: An inception cohort study. Br J Dermatol 2009;160:1075-82.
30. Weibel L, Sampaio MC, Visentin MT, Howell KJ, Woo P, Harper JI. Evaluation of methotrexate and corticosteroids for the treatment of localized scleroderma (morphoea) in children. Br J Dermatol 2006;155:1013-20.
31. Fitch PG, Rettig P, Burnham JM, Finkel TH, Yan AC, Akin E, et al. Treatment of pediatric localized scleroderma with methotrexate. J Rheumatol 2006;33:609-14.
32. Cox D, O' Regan G, Collins S, Byrne A, Irvine A, Watson R. Juvenile localised scleroderma: A retrospective review of response to systemic treatment. Ir J Med Sci 2008;177:343-6.
33. Roos N, Poulalhon N, Farge D, Madelaine I, Mauviel A, Verrecchia F. In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil. J Pharmacol Exp Ther 2007;321:583-9.
34. Shimizu H, Takahashi M, Takeda S, Inoue S, Fujishiro J, Hakamata Y, et al. Mycophenolate mofetil prevents transplant arteriosclerosis by direct inhibition of vascular smooth muscle cell proliferation. Transplantation 2004;77:1661-7.
35. Gao R, Lu Y, Xin YP, Zhang XH, Wang J, Li YP. The effects of different immunosuppressants on chronic allograft nephropathy by affecting the transforming growth factor-beta and Smads signal pathways. Transplant Proc 2006;38:2154-7.
36. Derk CT, Grace E, Shenin M, Naik M, Schulz S, Xiong W. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology (Oxford) 2009;48:1595-9.
37. Petrova DT, Brehmer F, Schultze FC, Asif AR, Gross O, Oellerich M, et al. Differential kidney proteome profiling in a murine model of renal fibrosis under treatment with mycophenolate mofetil. Pathobiology 2011;78:162-70.
38. Manzia TM, Angelico R, Toti L, Bellini MI, Sforza D, Palmieri G, et al. Long-term, maintenance MMF monotherapy improves the fibrosis progression in liver transplant recipients with recurrent hepatitis C. Transpl Int 2011;24:461-8.
39. Scheel PJ Jr, Feeley N, Sozio SM. Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis: A case series. Ann Intern Med 2011;154:31-6.
40. Strauss RM, Bhushan M, Goodfield MJ. Good response of linear scleroderma in a child to ciclosporin. Br J Dermatol 2004;150:790-2.
41. Crespo MP, Mas IB, Diaz JM, Costa AL, Nortes IB. Rapid response to cyclosporine and maintenance with methotrexate in linear scleroderma in a young girl. Pediatr Dermatol 2009;26:118-20.
42. Neustadter JH, Samarin F, Carlson KR, Girardi M. Extracorporeal photochemotherapy for generalized deep morphea. Arch Dermatol 2009;145:127-30.
43. Kaur S, Dhar S, Kanwar AJ. Treatment of childhood linear morphea with D-penicillamine. Pediatr Dermatol 1993;10:201-2.
44. Van Bergen BH, Van Dooren-Greebe RJ, Fiselier TJ, Koopman RJ. D-penicillamine in treatment of scleroderma "en coup de sabre". Hautarzt 1997;48:42-4.
45. Moinzadeh P, Krieg T, Hunzelmann N. Imatinib treatment of generalized localized scleroderma (morphea). J Am Acad Dermatol 2010;63:e102-4.
46. Diab M, Coloe JR, Magro C, Bechtel MA. Treatment of recalcitrant generalized morphea with infliximab. Arch Dermatol 2010;146:601-4.